Study of Elironrasib (RMC-6291) and Daraxonrasib (RMC-6236) With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A
Key facts
- Where
- A Coruña, Badalona, Barcelona, Madrid, Málaga, Pamplona, Sevilla és Valencia, SpanyolországSee the 13 sites
- Phase
- 1. fázis
Where in Spanyolország
- Complexo Hospitalario Universitario A CoruñaA Coruña, SpanyolországTaking people
- Institut Catala d'OncologiaBadalona, SpanyolországTaking people
- Hospital Universitari Vall d'HebronBarcelona, SpanyolországTaking people
- Clinica Universidad de NavarraMadrid, SpanyolországTaking people
- Hospital Clínico San CarlosMadrid, SpanyolországTaking people
- Hospital Universitario 12 de OctubreMadrid, SpanyolországTaking people
- Hospital Universitario Fundación Jiménez DíazMadrid, SpanyolországTaking people
- Hospital Universitario Ramón y CajalMadrid, SpanyolországTaking people
- Hospital Universitario Regional de MálagaMálaga, SpanyolországTaking people
- Clínica Universidad de navarraPamplona, SpanyolországTaking people
- University Hospital Virgen Del Rocio S.L.Sevilla, SpanyolországTaking people
- Fundación Instituto Valenciano de OncologíaValencia, SpanyolországTaking people
- Hospital Universitario Y Politecnico La FeValencia, SpanyolországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Revolution Medicines Inc.
- Trial code
- EU 2023-509571-16-00
- Record updated
- 2026. október 9.
- Original description
To evaluate the safety and tolerability of elironrasib in combination with pembrolizumab, with or without daraxonrasib, with or without chemotherapy, in patients with advanced RAS G12C-mutated solid tumors To define the RP2DS for elironrasib in combination with pembrolizumab, with or without daraxonrasib, with or without chemotherapy, in patients with advanced RAS G12C-mutated NSCLCRead full original descriptionShow less
Study of Elironrasib (RMC-6291), With or Without Daraxonrasib (RMC-6236), in Combination With Other Anti-Cancer Agents, in Patients With RAS G12C-Mutated Non-Small Cell Lung Cancer – Subprotocol A
To evaluate the safety and tolerability of elironrasib in combination with pembrolizumab, with or without daraxonrasib, with or without chemotherapy, in patients with advanced RAS G12C-mutated solid tumors To define the RP2DS for elironrasib in combination with pembrolizumab, with or without daraxonrasib, with or without chemotherapy, in patients with advanced RAS G12C-mutated NSCLC
Inclusion: ≥ Patients that are at least 18 years old, or legal age of consent. 2. Patients that have solid tumor with RAS-G12C. 3. Patients that have received prior cancer treatment or are not able to tolerate regular treatments. 4. Patients that have at least one tumor lesion (an area of abnormal tissue) that can be measured. 5. Patients that have adequate organ function (bone marrow, liver, kidney).
Exclusion: Participants that have primary brain and spinal cord tumor. 2. Participants thathave gastrointestinal problems that may affect absorption of elironrasib. 3. Participants thathad any major surgery in the last 4 weeks. 4. Participants thathave any other medical condition that may interfere with the study drugs. 5. Participants that have previously taken targeted therapy for KRAS mutation. 6. Participants that need other medicines, eat foods, or receive treatments that may interfere with the study drugs.